Effective Management of Psoriatic Arthritis: Tailoring Treatments

Slides:



Advertisements
Similar presentations
GRAPPA Guidelines for PsA: Considerations GRAPPA Guidelines Mission Statement: “To develop guidelines, based upon the best scientific evidence, for the.
Advertisements

OMERACT 8 PsA Module Proposal Submitted by: Dafna Gladman and Philip Mease.
Psoriatic Arthritis Workshop OMERACT 7 Steering Committee Dafna Gladman, Philip Mease, Gerald Krueger, Désirée van der Heijde, Christian Antoni, Philip.
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis R1 신가영 / Modulator Prof. 이연아 N Engl J Med 2015; 373: Philip J.
4. Rheumatologic conditions
Systemic Lupus Erythematosus
Clinical Trials in IBD.
New Psoriasis Treatments
Psoriatic Arthritis.
Evolution of Treatment Strategies Targeting IL-23 for Psoriasis
IL-12 and IL-23.
Introduction/Background
Clinical Developments in Inflammatory Arthritis 2017
Introduction/Background
Dry AMD and GA: The Present and Future
Progression After Cancer Immunotherapy in Advanced NSCLC
Introduction. Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Endocrine System.
Introduction to Checkpoint Inhibitors
Part 1: Disease Activity Measures
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
From Conference to Practice: Big Data in Psoriasis
Cancer Stem Cell Therapies in Gastrointestinal Cancers
The ABCs of Nitric Oxide in the Skin
IL-17 Inhibitors in the Management of Psoriatic Disease
Tailoring Hemophilia Prophylaxis Therapy
Asthma and Atopic Comorbidities
A Focus on Polycythemia Vera for Nurse Practitioners and Physician Assistants.
Precision Management of RA and Comorbidities
Christian A. von Hehn, Ralf Baron, Clifford J. Woolf  Neuron 
The Emerging Role of Immunotherapy in Hodgkin Lymphoma
Contemporary Issues in Psoriasis Care: A Call to Action
Next-Gen Psoriasis Therapies:
Managing IBD.
Gene Therapy: Past, Present, and Future
Atopic Dermatitis. Introduction to a Clinical Course On New Developments In Atopic Dermatitis.
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Immunotherapy for cSCC
The JAK-STAT Pathway and Graft-vs-Host Disease
Evolving Treatment Landscape for PsA
Personalized Therapy in Relapsed or Refractory CLL
Improving Outcomes in Psoriatic Arthritis
Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis.
Pathogenic mechanisms involved in psoriasiform skin lesions during anti-TNF-α therapy. Pathogenic mechanisms involved in psoriasiform skin lesions during.
Intro: Biomarkers in RA
Updated 2016 PsA Core Domain Set.
What's New in Therapeutic Options for Moderate to Severe RA?
Advancing Patient Care in RA
Understanding and Addressing the Needs of Patients With AD
Advances in Severe Asthma Management
Challenges in Severe Asthma
Ask the Psoriasis Expert
Breaking News in Pemphigus Vulgaris and the Latest Updates for Your Practice.
Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.
Patient Questions and Expert Answers in Psoriasis:
Severe Asthma and Comorbidities
Update on the Management of Atopic Dermatitis
EXPERT INSIGHTS: IL-17 INHIBITION IN PSORIASIS CARE
Updates in RA, PsA, and Biosimilars
A speculative scheme representing physiopathological mechanisms and clinical manifestations of psoriatic disease. A speculative scheme representing physiopathological.
Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
Targeting IL-23 for Therapeutic Longevity in Psoriasis
Understanding How IL-23p19 Inhibitors Work in Psoriasis
Behçet Syndrome (BS) Overview
Enthesitis in Psoriatic Arthritis: Disease, Diagnosis and Decisions
Meet the JAKs.
Motor Fluctuations in PD
Psoriatic Arthritis.
You Don't Know JAK in IBD.
Women With Psoriasis Are Struggling More Than Men
Presentation transcript:

Effective Management of Psoriatic Arthritis: Tailoring Treatments

Psoriatic Arthritis Clinical Manifestations

Psoriatic Arthritis Clinical Manifestations (cont)

Psoriatic Arthritis Clinical Manifestations (cont)

Psoriatic Arthritis Comorbidities

Psoriatic Arthritis Contributing Factors to Psoriasis

Key Cells and Mediators: Transition From Innate to Adaptive Immunity

Pathogenesis of Psoriatic Arthritis

Treatment of Psoriatic Arthritis

Newer Treatment Options

Emerging Treatments for Psoriatic Arthritis

Treatment of Psoriatic Arthritis The Pathophysiologic Cascade

Cytokine Signaling Pathways cAMP/PKA

Ustekinumab Inhibits p40 Moiety

IL-17 Inhibitors

Cytokine Signaling Pathways JAK

Mechanism of Action of Abatacept

Guselkumab: IL-23, p19

New Domain Core Set for Psoriatic Arthritis

Core Domains to Evaluate in Clinical Trials

GRAPPA 2015 Treatment Recommendations

GRAPPA 2015 Treatment Recommendations: Peripheral Arthritis

GRAPPA 2015 Treatment Recommendations: Axial Disease

GRAPPA 2015 Treatment Recommendations: Enthesitis and Dactylitis

GRAPPA 2015 Treatment Recommendations: Skin and Nails

Case: Aggressive Disease 55-Year-Old Man

Joint Examination

Choosing a Therapy

GRAPPA Minimal Disease Activity Criteria

Case: Disease Progression 40-Year-Old Woman

Evaluation for Inflammatory Back Pain

Treatment and Management

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)